Literature DB >> 24009784

Global elimination of lymphatic filariasis: a "mass uprising of compassion".

David G Addiss1.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 24009784      PMCID: PMC3757069          DOI: 10.1371/journal.pntd.0002264

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


× No keyword cloud information.

Introduction

Hospitals and medical centers often cite compassion as a core value in their mission statements. In contrast, the importance of compassion in global health is rarely acknowledged, even though it is a significant source of motivation and sustenance for those working in the field. The Global Programme to Eliminate Lymphatic Filariasis (GPELF) provides an illustrative example of the role and promise of compassion in global health. It was established in 1998 to alleviate and prevent immense human suffering caused by the neglected tropical disease (NTD) lymphatic filariasis (LF). From its beginning, the GPELF was conceived as having two “pillars”: one to interrupt transmission of the parasites that cause LF and the other to care for those who already have LF-related disease [1]. Inclusion of a morbidity management pillar distinguished the GPELF from efforts to eradicate smallpox, polio, and Guinea worm disease, which focused primarily, if not exclusively, on interrupting transmission. This two-pronged approach was initially criticized on the basis that efforts to reduce the suffering of those affected would divert attention and resources from the principal goal of stopping LF transmission [2]. Despite these reservations, the GPELF adopted morbidity management for three main reasons. First, the World Health Assembly (WHA) resolution that launched the GPELF (WHA 50.29) called for eliminating LF “as a public health problem.” The public health problem in question was not microfilaremia, but rather the stigmatizing and disfiguring conditions of lymphedema, affecting some 15 million persons, and hydrocele, affecting some 25 million men. Second, it was thought that providing clinical care to those who already had LF-related disease could enhance the acceptability of preventive chemotherapy to interrupt transmission. Cantey and colleagues recently documented this beneficial effect in a study from Orissa, India [3]. Finally, and most importantly, relieving suffering through morbidity management was considered the right thing to do. Compassion demanded it.

Compassion and the GPELF

Social psychology teaches that compassion is comprised of three key elements: cognitive awareness, emotional resonance, and compassionate action. The GPELF is characterized by all three. First, a compassionate response to suffering requires that one first be aware of its existence. In a speech to the Centers for Disease Control and Prevention (CDC) in 1984, Bill Foege said: “If we are to maintain the reputation this institution now enjoys, it will be because in everything we do, behind everything we say, as the basis for every program decision we make—we will be willing to see faces.” This was an extraordinary message for a major public health institution with responsibilities for the health of populations, not individuals. The CDC's reputation would depend not on programmatic effectiveness, measurable outcomes, or epidemiologic prowess, but on compassion—the willingness of its employees, collectively, to see the faces of suffering. Many who established the GPELF had studied LF as scientists and they were acutely aware of the personal suffering, stigmatization, and disability that it caused. They had seen the faces—and could not forget them. Inspired by the pioneering clinical work of Dr. Gerusa Dreyer in Brazil [4] and Professor R.K. Shenoy in India [5], they insisted that priority be given to relieving LF-related suffering. During the past two decades, our collective awareness of the magnitude and nature of this suffering has grown tremendously, thanks to excellent studies by social scientists in Ghana, Brazil, Haiti, the Dominican Republic, India, and elsewhere (summarized in [6]). Second, compassion requires emotional attunement or empathy—the ability to feel the suffering of the other. The LF program has engaged the emotions since it began. A 1997 booklet by the World Health Organization (WHO) that promoted the cause of LF elimination was punctuated with sentences from a letter by a Ghanaian woman with advanced LF-related lymphedema [7]. “Dear sir,” she begins, “I am writing with the hope that you can help me.” A few pages later, she continues: “I kneel and plead to be touched by your innermost heart for a humanitarian feeling, to try and do your best to help me.” Although the role of emotion as a motivating force, either individually or collectively, is rarely discussed, virtually everyone who is actively engaged in LF elimination has a story, a lived experience of human suffering that was deeply moving—and that lies at the core of their motivation for the work. Third, compassion is characterized by action. The Fourteenth Dalai Lama said that compassion “is not just a wish to see sentient beings free from suffering, but an immediate need to intervene and actively engage, to try to help…A person who has attained stability in his or her compassion training…should now be out, running around like a mad dog, actively engaged in acts of compassion” [8]. By any standard, the action mobilized by the GPELF to eliminate LF-related suffering for future generations has been “mad dog” impressive. Some 3.9 billion preventive chemotherapy treatments have been delivered since 2001. The GPELF is one of the most rapidly upscaling programs in public health history, having engaged hundreds of thousands of workers and now treating more than 500 million persons each year [9].

Are We Seeing the Faces?

Unfortunately, the morbidity management pillar, which WHO describes as “rooted in compassion” [10], has not fared as well. In 2011, 53 of 73 LF-endemic countries had preventive chemotherapy programs, while only 27 reported activities in morbidity management [10]. Several reasons likely contribute to this. Preventive chemotherapy has proven such a powerful intervention for interrupting LF transmission that most of the attention and resources in the GPELF have been devoted to scaling it up. Because of its success, preventive chemotherapy has become the overriding organizing principle not only for the elimination of LF, but also for the control of other NTDs [11], [12]. In addition, recommended procedures and guidelines for management of hydrocele and lymphedema in LF-endemic areas were not well-established when the GPELF began. Further, effective national programs to manage lymphedema and hydrocele require extensive collaboration with clinical health services, beyond the purview and experience of many LF program managers. A more nuanced and sophisticated matrix approach toward LF morbidity management is emerging that mobilizes surgical services to manage urogenital LF and integrates lymphedema management with clinical care for conditions such as diabetic foot, leprosy, and Buruli ulcer [13]. In many areas, this integrated approach, although not “solely owned” by the LF program, will be essential for the LF program to achieve its goals. A more subtle and pervasive reason for the slow uptake of morbidity management in the GPELF lies in the corrosive forces that inhibit and obstruct compassion in many global health programs. Sustaining the empathic connection required for compassion—seeing the faces behind the numbers—is difficult when working to improve the health of hundreds of millions of people, across great geographic distances. What does it mean to have compassion for entire populations? The global scope of the LF program requires the collaboration of many complex organizations, often with competing agendas and historic rivalries. Motivations other than compassion, such as economic profit, political and military hegemony, and personal ambition, are notoriously active. Our collective silence on compassion in our work isolates us as individuals and allows these other forces to operate unchallenged.

Addressing the Challenges

Much remains to be done if the 2020 target for LF elimination is to be met [10]. In addition to addressing the remaining technical, logistical, and financial challenges, it will be necessary to simultaneously attend to four pairs of activities, each of which holds the tension of paradox. First, we need to maintain focus on eliminating transmission and expand our peripheral vision to include, to a much greater extent, those with LF disease. The two pillars are complementary and mutually reinforcing, not conflicting. Second, extending the benefits of the GPELF to those who currently suffer from LF-related disease will require national LF elimination programs that are cohesive and unified and that engage different sectors of the health care system—a more sophisticated and collaborative approach. Third, we need to be able to see the faces and the numbers—and to do this at the same time [14]. Finally, we need to combine compassion for individuals with action at the population level. How might we begin to see both the faces and the numbers, to combine compassion for individuals with action at the population level? We might start by sharing our stories, by venturing to speak more openly about the compassion that motivates our work and sustains our spirits. Many of us find that travel to the field, literally to “see the faces,” revitalizes our efforts to improve the health of populations. We keep photos in our workplace that remind us of individuals whose lives have touched us. As we break our collective silence on compassion, other possibilities and practices will undoubtedly emerge. The late Steve Ben Israel, an American comedian, anarchist, and performance artist, said that the intent of his life's work was to “foment a mass uprising of compassion” [15]. While the GPELF has not fully extended the benefits it initially promised to those with LF-related disease, as a global response to human suffering, it represents a spectacular—if unfinished—mass uprising of compassion. By connecting more deeply with the compassionate impulse within us, by cultivating the capacity to be fully present to the faces of suffering, we will be better equipped, individually and collectively, to realize the GPELF's tremendous potential.
  7 in total

Review 1.  Controlling morbidity and interrupting transmission: twin pillars of lymphatic filariasis elimination.

Authors:  A R Seim; G Dreyer; D G Addiss
Journal:  Rev Soc Bras Med Trop       Date:  1999 May-Jun       Impact factor: 1.581

Review 2.  Control of neglected tropical diseases.

Authors:  Peter J Hotez; David H Molyneux; Alan Fenwick; Jacob Kumaresan; Sonia Ehrlich Sachs; Jeffrey D Sachs; Lorenzo Savioli
Journal:  N Engl J Med       Date:  2007-09-06       Impact factor: 91.245

3.  Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution.

Authors:  J Utzinger; G Raso; S Brooker; D De Savigny; M Tanner; N Ornbjerg; B H Singer; E K N'goran
Journal:  Parasitology       Date:  2009-11       Impact factor: 3.234

4.  Global elimination of lymphatic filariasis: addressing the public health problem.

Authors:  David G Addiss
Journal:  PLoS Negl Trop Dis       Date:  2010-06-29

5.  Increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs.

Authors:  Paul T Cantey; Jonathan Rout; Grace Rao; John Williamson; LeAnne M Fox
Journal:  PLoS Negl Trop Dis       Date:  2010-06-29

6.  Clinical and pathological aspects of filarial lymphedema and its management.

Authors:  R K Shenoy
Journal:  Korean J Parasitol       Date:  2008-09       Impact factor: 1.341

Review 7.  The emerging story of disability associated with lymphatic filariasis: a critical review.

Authors:  Lynne Michelle Zeldenryk; Marion Gray; Richard Speare; Susan Gordon; Wayne Melrose
Journal:  PLoS Negl Trop Dis       Date:  2011-12-27
  7 in total
  6 in total

1.  Synthesis of silver and gold nanoparticles using Jasminum nervosum leaf extract and its larvicidal activity against filarial and arboviral vector Culex quinquefasciatus Say (Diptera: Culicidae).

Authors:  H Lallawmawma; Gnanasekar Sathishkumar; Subburayan Sarathbabu; Souvik Ghatak; Sivaperumal Sivaramakrishnan; Guruswami Gurusubramanian; Nachimuthu Senthil Kumar
Journal:  Environ Sci Pollut Res Int       Date:  2015-07-09       Impact factor: 4.223

Review 2.  Trachoma.

Authors:  Anthony W Solomon; Matthew J Burton; Emily W Gower; Emma M Harding-Esch; Catherine E Oldenburg; Hugh R Taylor; Lamine Traoré
Journal:  Nat Rev Dis Primers       Date:  2022-05-26       Impact factor: 52.329

3.  Pan-phylum Comparison of Nematode Metabolic Potential.

Authors:  Rahul Tyagi; Bruce A Rosa; Warren G Lewis; Makedonka Mitreva
Journal:  PLoS Negl Trop Dis       Date:  2015-05-22

4.  PLOS Neglected Tropical Diseases: Ten years of progress in neglected tropical disease control and elimination … More or less.

Authors:  Peter Hotez; Serap Aksoy
Journal:  PLoS Negl Trop Dis       Date:  2017-04-20

5.  Essential proteins and possible therapeutic targets of Wolbachia endosymbiont and development of FiloBase--a comprehensive drug target database for Lymphatic filariasis.

Authors:  Om Prakash Sharma; Muthuvel Suresh Kumar
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

6.  Modeling the Parasitic Filariasis Spread by Mosquito in Periodic Environment.

Authors:  Yan Cheng; Xiaoyun Wang; Qiuhui Pan; Mingfeng He
Journal:  Comput Math Methods Med       Date:  2017-02-08       Impact factor: 2.238

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.